GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » Short Percentage of Float

Karolinska Development AB (Karolinska Development AB) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Karolinska Development AB's Short Percentage of Float

For the Biotechnology subindustry, Karolinska Development AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's Short Percentage of Float falls into.



Karolinska Development AB (Karolinska Development AB) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.